A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine (NCT06602479)
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine
π©Ί Plain-English Summary (8th-Grade Level)
The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.
Who can join: Review the eligibility criteria below.
Location: Flourish - Birmingham β Birmingham, Alabama
Age range: 18 Years to 70 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (54 Sites)
Showing the first 25 of 54 sites.
- Flourish - Birmingham β Birmingham, Alabama
- Tennessee Valley Neurological Associates PC β Huntsville, Alabama
- The Neurology Center of Southern California - Carlsbad Office β La Jolla, California
- Clinical Research Institute, LCC β Los Angeles, California
- Homestead Associates in Research, Inc. β Homestead, Florida
- Florida Neurology - Lake Mary β Lake Mary, Florida
- Flourish Research - Miami, LLC dba Flourish Research β Miami, Florida
- BayCare Medical Group Neurology at St. Anthony's Hospital β St. Petersburg, Florida
- Santos Research Center, Corp - Tampa β Tampa, Florida
- Norton Neuroscience Institute - Headache Clinic β Louisville, Kentucky
- Modern Migraine, MD β New York, New York
- Velocity Clinical Research, Providence (East Greenwich) β East Greenwich, Rhode Island
- Palmetto Primary Care Physicians Division of Gastroenterology - Summerville β Summerville, South Carolina
- FutureSearch Trials β Austin, Texas
- Vaught Neurological Services, PLLC β Crab Orchard, West Virginia
- The Mind+ Neurology Clinic β Mequon, Wisconsin
- Brain-Soultherapy s.r.o. β Kladno,
- Clintrial s.r.o. β Prague,
- DADO Medical s.r.o. β Prague,
- Axon Clinical s.r.o. β Prague,
- Praglandia s.r.o. β Prague,
- Forbeli s.r.o β Prague,
- Institut Neuropsychiatricke Pece (INEP) β Prague,
- Vestra Clinics s.r.o. β Rychnov nad KnΔΕΎnou,
- Rigshospitalet (Copenhagen University Hospital) - Dansk Hovedpinecenter (Danish Headache Center) β Glostrup Municipality,
π Contact the Study Coordinator
Phone: (844) 663-3742
Email: abbvieclinicaltrials@abbvie.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Migraine
- A Study of Wearable Devices to Predict Migraines β Rochester, Minnesota
- Treatment for Migraine and Mood β The Bronx, New York
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine β Birmingham, Alabama
- A Study to Evaluate White Matter Hyperintensities in Migraine β Phoenix, Arizona
- Migraine Manager (R01) β Cincinnati, Ohio
- Nerivio Efficacy Under High-Frequency Use β Bridgewater, New Jersey
Explore by condition: All Migraine clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.